Mission Statement

NANOS Mission Statement:
 

The North American Neuro-Ophthalmology Society (NANOS) is dedicated to achieving excellence in care of patients with neuro-ophthalmic diseases by the support and promotion of education, research, and the practice of neuro-ophthalmology.
 

NANOS CME Mission Statement:


The North American Neuro-Ophthalmology Society (NANOS) is dedicated to achieving excellence in care of patients with neuro-ophthalmic diseases by the support and promotion of education, research, and the practice of neuro-ophthalmology.

The Society’s main CME activity is its annual scientific meeting. The educational meeting includes seminars, workshops, hands-on training, platform presentations, and discussion of cases and best practices in neuro-ophthalmic research, basic science, and patient care. 

The CME goal of the meeting is to improve the attendees’ knowledge of neuro-ophthalmology basic science and practice.  More specifically, the goals of the meeting are: 

1)  To achieve competence in neuro-ophthalmic diagnosis, treatment, and teaching; 2) To improve performance as physicians, teachers, and researchers by using information presented at the meeting to change clinical practice and instruction; and 3) To review research projects to investigate questions raised by the meeting’s scientific sessions.

The expected results of our CME program, and of our annual meeting as its main CME activity, is that our members will increase their knowledge of neuro-ophthalmology and improve their skill in its practice, so that they can apply that knowledge and skill to enhance their performance and competence as clinical neuro-ophthalmologists, research neuro-ophthalmologists, and teachers of neuro-ophthalmology.

 

NANOS uses multiple data sources to measure the impact of its educational activities on learners and on the discipline of neuro-ophthalmology.  These sources translate professionals’ need into current practices to improve competence in knowledge, diagnosis, performance, and treatment of neuro-ophthalmic diseases. 


Approved by the NANOS CME Subcommittee and NANOS Board of Directors as of 2015